Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 31, 2008

Egenix and Millennium Tap Harvard Medical School Expertise through Separate Agreements

  • Harvard Medical School granted Egenix rights to discoveries related to cancer drug development as well as inked a license and research agreement with Millenium Pharmaceuticals’ focused on protein homeostasis.

    Egenix’ licensed technologies comprise small molecule inhibitors of translation initiation and the use of translation initiation-specific biomarkers to assess tumor sensitivity to anticancer therapy.

    The licensed inhibitors of translation initiation target the eIF4F and ternary complexes, two regulators of mRNA translation into protein. Egenix believes that small molecules for the inhibition of translation initiation are at the forefront of modern cancer therapeutics currently under development and that this platform has the potential.

    Separately, Millennium Pharmaceuticals’ licensed protein homeostasis research from Harvard Medical School. The parties will jointly advance the program under a sponsored research agreement.

    Studies have shown various pathways that regulate cellular protein homeostasis are linked to the pathologic properties of a broad range of cancers, the collaborators remark. The initial research-based agreement is focused on advancing knowledge in this evolving field over the course of three years.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »